Objective: To identify determinants of pulmonary function and health-related quality of life (HRQOL) to better understand disease severity in patients with asthma and COPD. Design: Observational study. Setting: Dutch general practice. Patients: We studied 837 asthma patients and 231 COPD patients.
B
oth asthma and COPD, including pulmonary emphysema and chronic bronchitis, are diseases characterized by airway obstruction; consequently, their clinical manifestations overlap. However, there are also many differences between the two diseases with respect to their pathogenesis, pathophysiology, response to therapy, and prognosis. 1 There is no single criterion by which severity of disease in asthma and COPD may be adequately described. Several outcome measures in the assessment of disease severity are used. The most commonly used way to express disease severity in asthma and COPD is by assessing the FEV 1 as a measure of airway obstruction. FEV 1 is, besides age, considered to be the most important predictor of mortality in patients with COPD. 2, 3 Both the American Thoracic Society and the European Respiratory Society recommended a staging system for the assessment of COPD severity on the basis of actual FEV 1 as a percentage of predicted (FEV 1 %pred). 4, 5 Also in asthma patients, the level of airway obstruction expressed as FEV 1 %pred is used for classifying the extent of (temporary or permanent) airway obstruction. 6 Whether a low FEV 1 %pred is also a predictor of mortality in asthma patients remains to be established. In a recent study, 7 prognosis in terms of all-cause mortality was found to be strongly associated with age, smoking, and the best attainable FEV 1 %pred in COPD as well as in asthma patients. However, these asthma patients were older (mean age, 53.4 years) and also had partly irreversible airway obstruction.
Another approach of severity assessment that in this last decade is recognized to be important is to assess the subjective influence of the disease on a patient's quality of life using a health-related quality of life (HRQOL) questionnaire. HRQOL has become an important outcome parameter to assess patients' subjective experience of the effects of disease and treatment on satisfaction with life. HRQOL can be measured by means of generic or disease-specific questionnaires. Disease-specific questionnaires focus on the influence of characteristics of a particular disease on functioning, while generic questionnaires focus on the influence of general health status on functioning. Several diseasespecific questionnaires have been developed for the evaluation of HRQOL in patients with asthma, COPD, or for both diseases. 8 Because both HRQOL and FEV 1 are regarded as important measures of disease severity in asthma and COPD, intuitively one would expect these entities to be strongly associated. However, weak or no associations at all are found between FEV 1 and scores on several generic and disease-specific HRQOL questionnaires in asthma and COPD. 9 -16 Curtis et al 9 reviewed patient and disease characteristics that were associated with HRQOL in COPD patients. In order of strength of association, they are as follows: dyspnea, depression, anxiety, exercise tolerance, FEV 1 , FVC, age, socioeconomic status, and educational level. In asthma, HRQOL scores were found to be weakly to moderately associated with symptom score, bronchodilator use for the relief of symptoms, morning peak expiratory flow (PEF), bronchial hyperresponsiveness (BHR), educational level, and gender. 15, [17] [18] [19] In studies 20, 21 examining FEV 1 as an outcome measure, some similar but also some different determinants were found. Among asthmatic patients, FEV 1 %pred was found to be associated with severity of symptoms, wheeze, dyspnea, age, and a concurrent diagnosis of chronic bronchitis. However, in a similar population, Teeter and Bleecker 22 did not find a significant relationship between any individual symptom (cough, chest tightness, dyspnea, sputum production, nocturnal awakening) and FEV 1 %pred. In COPD patients, FEV 1 %pred was found to be moderately associated with the patients' ratings of dyspnea. [23] [24] [25] Weaver et al 26 found FEV 1 to be directly associated with exercise capacity but not with dyspnea. Also, Bestall et al 27 did not find an association between FEV 1 %pred and dyspnea in patients with severe COPD.
It is difficult to compare or summarize results of different studies because there is considerable heterogeneity in outcome measures, instruments used, and study populations included. This makes it difficult to identify determinants associated with FEV 1 %pred and with HRQOL. Identifying these determinants might give a better understanding of the concept of disease severity in patients with asthma and COPD. This study examines both patient groups separately in order to identify similarities and differences in the determinants of pulmonary function and HRQOL.
Materials and Methods

Patients
Cross-sectional analyses were performed using the baseline measurements of a longitudinal study examining the course and consequences of asthma and COPD in Dutch general practice. Thirty-one general practitioners from 25 practices in two rural regions in the east and northwest, and one urban region in the west of The Netherlands selected all patients registered with a diagnosis of asthma or COPD. Diagnoses of chronic nonspecific lung disease (including asthma and COPD) recorded in general practices in The Netherlands are generally in line with international standard diagnostic criteria for general practice. 28 Of those selected, only patients who met the following inclusion criteria were included in the study: age, 16 to 75 years; capability of filling in a Dutch questionnaire; no specific pulmonary disease other than asthma or COPD (such as localized disease of the upper airways, bronchiectasis, and cystic fibrosis); and absence of any disease in a terminal phase. Informed consent to participate was obtained. Baseline measurements were conducted between 1995 and 1998 and included patients with newly diagnosed conditions.
The distinction between asthma and COPD was made by the researcher using the baseline pulmonary function measurements (see below), following the 1997 revised guidelines ("standard") 29 of the Dutch College of General Practitioners (Nederlands Huisartsen Genootschap) for the diagnosis of asthma and COPD. Asthma was defined as follows: (1) a prebronchodilator FEV 1 %pred of Ն 80%; or (2) a combination of a prebronchodilator FEV 1 %pred of Ͻ 80%, a reversible obstruction (increase in FEV 1 10 min after administration of a bronchodilator of Ͼ 9% of predicted), and a postbronchodilator FEV 1 %pred of Ն 80%. COPD was defined as follows: a prebronchodilator FEV 1 %pred of Ͻ 80% combined with an irreversible obstruction (variation in FEV 1 before and after bronchodilation of Ͻ 9% of predicted). Patients with a prebronchodilator FEV 1 %pred of Ͻ 80%, a reversible obstruction, and a postbronchodilator FEV 1 %pred of Ͻ 80% were defined as having a mixed disease (asthma with persisting airway obstruction). Characteristics of the latter group are presented, but these patients were excluded from further analyses.
Outcome Variables
The outcome variables measured were FEV 1 and HRQOL. FEV 1 was measured according to American Thoracic Society criteria 30 before and after administration of a bronchodilator (salbutamol, 400 g), using a hand-held spirometer (SpiroSense; Tamarac Systems; Denver, CO) in the west study site and east study site, and a dry rolling-seal spirometer (MasterScreen CS-FRC; Jaeger-Toennies; Hoechberg, Germany) in the northwest study site. Patients were instructed not to use bronchodilators on the day of pulmonary function assessment. Personnel were especially trained by qualified laboratory technicians to perform the pulmonary function measurements. Spirometers were calibrated daily with a 3-L syringe (west and east study sites) or a 2-L syringe (northwest study site). All patients were studied while in a sitting position wearing a nose clip. Data from the flow-volume curve with the highest sum of FVC and FEV 1 were used for calculations. FEV 1 was expressed as FEV 1 %pred, based on gender, height, and age, using the adult predicted normal values of the European Community for Coal and Steel. 31 HRQOL was measured using the Quality Of Life in Respiratory Illness Questionnaire of Maille et al, 32 which was handed out to the patients to be completed at home. This written questionnaire was especially developed and validated for patients with asthma and COPD treated primarily in general practice, who generally have mildly to moderately severe disease. It contains 55 items classified into seven subscales: (1) breathing problems; (2) physical problems; (3) emotions; (4) situations triggering or enhancing breathing problems; (5) general activities; (6) daily and domestic activities; (7) and social activities, relationships, and sexuality. For every item, patients were asked to answer, on a 7-point Likert-type scale, to what degree they were troubled because of pulmonary complaints. The response categories of all items ranged from 1 (not troubled at all) to 7 (very much troubled). As a measure of reliability, Cronbach's ␣ varied from 0.68 to 0.92 for the domain subscales, and was 0.92 for the overall scale. 32 In case of missing data, Ͻ 50% of missing items were allowed per subscale and were substituted, and one missing subscale was allowed for the calculation of the overall score. 33 Because the distribution of the overall HRQOL score was skewed in the asthma group (skewness, 1.31; SD, 0.07), this score was log-transformed for all analyses, which solved this problem. Furthermore, this log-HRQOL score was transformed in such a way that a lower score indicates a reduced quality of life. ; and region of living (east, northwest, west). Comorbidity was defined present if the patient suffered from any other chronic disease (such as diabetes mellitus, hypertension, cardiovascular disease, stroke, arthritis, or malignancies). Cigarette smoking habits were defined by assessing smoking status (never smoker, former smoker, or current smoker).
Determinants
Characteristics of Disease: The duration of the disease (in years) was assessed by asking the patient when pulmonary complaints had started. A blood sample was taken for the assessment of allergy, which was defined as present by a positive Phadiatop test result (Pharmacia AB; Uppsala, Sweden). 34 A 2-week diary chart, including questions on respiratory symptoms and peak flow assessment, was handed out to the patient to be completed at home. PEF was measured every morning and evening three times in the standing position (Personal Best Peak Flowmeter; Respironics; Pittsburgh, PA). Every day for 2 weeks, the single best morning and evening PEFs were noted on the diary chart. Variability in PEF was expressed as the mean diurnal (within-day) PEF variation:
ϫ 100, averaged over 14 days Each day, the patient also recorded whether the past day and night were disturbed by respiratory symptoms (yes or no). The (rounded) number of days and nights disturbed (Ͼ 2 weeks) by respiratory complaints was calculated by counting the average number of days and nights disturbed during 14 days together and dividing by two. For both the diurnal PEF variation and the number of days and nights disturbed by respiratory complaints, data were extrapolated in case of missing data when at least 10 days provided valid data. The degree of dyspnea was assessed using the Dutch version of Medical Research Council questionnaire. 35 The grades of dyspnea were defined as follows: (0) no dyspnea, (1) dyspnea when in a hurry, (2) dyspnea when walking with others on flat ground, (3) having to stop for breath when walking alone on flat ground, or dyspnea in rest. Wheezing was categorized as (0) never wheezed, (1) ever wheezed, (2) wheezed most days and nights, or attacks of shortness of breath with wheezing in rest. Chronic cough was defined present if the patient responded yes to the question if he or she was coughing almost every day for at least 3 mo/yr. Sputum production was defined present if the patient answered yes to the question if he or she produced sputum daily for at least 3 mo/yr. Subjective response to nonspecific irritants was used as a proxy measure for BHR because no objective measure, such as the methacholine challenge test, was available. BHR was assessed by asking the patient, "Do you regularly respond with dyspnea, coughing, or wheezing to one or more of the following stimulants: cooking vapors, cigarette smoke, exposure to smog or exhaust fumes, changes in temperature, physical activity, or foggy/humid weather?" BHR was considered present if the patient answered yes to one or more of these items. Although this operational definition of BHR is not widely validated, the questions are commonly used by general practitioners when obtaining a medical history in order to assess the presence of BHR. 29 Treatment of Disease: The types of medications (scored as yes or no) were classified into several subgroups. First, bronchodilators were classified into the following groups: (1) inhaled shortacting bronchodilators (␤ 2 -agonists, anticholinergics); (2) inhaled long-acting bronchodilators (␤ 2 -agonists); and (3) oral bronchodilators (short-acting ␤ 2 -agonists or theophyllines). Second, preventive medications were classified as follows: (1) inhaled corticosteroids, (2) inhaled cromoglycates, or (3) oral corticosteroids (prednisolone, prednisone).
Statistical Analysis
Data were analyzed using software (Statistical Package for Social Sciences, version 7.5; SPSS; Chicago, IL). All analyses were performed separately for the asthma group and the COPD group. First, all potential determinants were entered separately in bivariate linear regression models with the prebronchodilator FEV 1 %pred and the transformed overall HRQOL score (tHRQOL) as the respective dependent variables. Subsequently, multivariate models were constructed using a (manual) backward selection method, deleting those variables with the highest p values, until all remaining variables had a p value Յ 0.10. Because many patients had missing information on diurnal PEF variation and days/nights disturbed by respiratory complaints (n ϭ 219), an extra dummy variable was added to the multivariate model (1 ϭ missing information on both variables; 0 ϭ others). Patients with missing information on days/nights disturbed by respiratory complaints (n ϭ 116) but not on diurnal PEF variation had approximately the same mean prebronchodilator FEV 1 %pred, tHRQOL-score, and diurnal PEF variation as patients with a score of 1 day/night disturbed and were therefore also classified in this group. The results from the bivariate regression analyses did not change significantly after these adaptations. The R 2 was reported as a measure of the percentage of variance in the outcome parameter explained by the determinants in the model.
Results
A total of 2,047 patients with asthma or COPD met the inclusion criteria of this study. Of these patients, 722 refused to participate. These 722 patients were significantly (p Ͻ 0.01) younger (mean age, 43 years) and a higher percentage were male (50%), than the 1,325 patients willing to participate in the study (mean age, 46 years; 44% male). Of the 1,325 patients left, 190 patients (14%) were excluded from the analysis because they either had missing data on pulmonary function (n ϭ 13) or they did not complete the written questionnaire. These 190 patients did not differ from the 1,135 patients included, regarding gender distribution, mean pulmonary function (prebronchodilator FEV 1 %pred, postbronchodilator FEV 1 %pred, reversibility), and diagnosis (asthma/COPD/mixed disease). Patients excluded were significantly (p Ͻ 0.01) younger (mean age, 44 years) than those included (mean age, 48 years).
In Table 1 , the characteristics of the study group are presented separately for asthma (n ϭ 837), COPD (n ϭ 231), and mixed disease (n ϭ 67). Compared to the asthma group, patients with COPD (p Յ 0.05), in general, were older; were less educated; used inhaled long-acting bronchodilators, oral bronchodilators, and inhaled or oral corticosteroids more often; had higher diurnal PEF variations; had more days/nights disturbed by respiratory complaints; had higher dyspnea-grades; and had lower tHRQOL scores. Furthermore, compared to the asthma group, a higher percentage of patients were male, were (former or current) smokers, were nonallergic, and reported comorbidity. Patients with mixed disease were comparable to the COPD group on most characteristics, except that they more often used inhaled short-acting bronchodilators and presented with higher diurnal PEF variations (p Ͻ 0.05).
Low but significant (bivariate) associations were found between tHRQOL and prebronchodilator FEV 1 %pred for both asthma (␤ ϭ 0.10) and COPD (␤ ϭ 0.19). The results from the linear regression analyses with prebronchodilator FEV 1 %pred and tHRQOL as dependent variables are given in Table  2 (bivariate) and Table 3 (multivariate). For the asthma group, in order of strength of association, the following characteristics were (multivariately) found to be associated with a lower prebronchodilator FEV 1 %pred (p Յ 0.05): higher diurnal PEF variation (␤ ϭ Ϫ 0.21), male gender (␤ ϭ Ϫ 0.14), longer duration of disease (␤ ϭ Ϫ 0.14), current smoking (␤ ϭ Ϫ 0.13), and use of inhaled short-acting bronchodilators (␤ ϭ Ϫ 0.10). Living in the west was associated with a higher prebronchodilator FEV 1 %pred (␤ ϭ 0.15). The percentage of variance in prebronchodilator FEV 1 %pred explained by the determinants in the reduced multivariate model was 16%. When tHRQOL was added, no significant improvement of the model was observed (data not presented in Tables) .
For COPD, the following characteristics were found to be associated with a lower prebronchodilator FEV 1 %pred (p Յ 0.05) in the multivariate model: use of inhaled long-acting bronchodilators (␤ ϭ Ϫ 0.31), use of inhaled short-acting bronchodilators (␤ ϭ Ϫ 0.16), more days/nights disturbed by respiratory complaints (␤ ϭ Ϫ 0.15), male gender (␤ ϭ Ϫ 0.14), and BHR (␤ ϭ Ϫ 0.13). A significantly higher prebronchodilator FEV 1 %pred was found for those who ever wheezed (␤ ϭ 0.19). The percentage of variance in prebronchodilator FEV 1 %pred explained by the determinants in the reduced multivariate model was 36%. By adding tHRQOL to the model, the variance explained increased to 38% (␤ ϭ 0.13; data not presented in Tables).
In the asthma group, a lower tHRQOL score was multivariately found to be most strongly associated with dyspnea (␤ ϭ Ϫ 0.28) and more days/nights disturbed by respiratory complaints (␤ ϭ Ϫ 0.27). Furthermore, associations (p Յ 0.05) were found with wheezing most days and nights (␤ ϭ Ϫ 0.14), BHR (␤ ϭ Ϫ 0.12), being younger (␤ ϭ 0.11), chronic cough (␤ ϭ Ϫ 0.11), use of inhaled shortacting bronchodilators (␤ ϭ Ϫ 0.11) and corticosteroids (␤ ϭ Ϫ 0.07), living in the east (␤ ϭ Ϫ 0.10) or west (␤ ϭ Ϫ 0.09), comorbidity (␤ ϭ Ϫ 0.08), and sputum production (␤ ϭ Ϫ 0.08). A higher educational level was associated with a higher tHRQOL score (␤ ϭ 0.09). The percentage of variance in tHRQOL explained by the determinants in the reduced multivariate model was 43%. The model was not improved by adding prebronchodilator FEV 1 %pred (data not presented in Tables).
For COPD, days/nights disturbed by respiratory complaints (␤ ϭ Ϫ0.32) and dyspnea (␤ ϭ Ϫ 0.27) were (multivariately) found to be most strongly associated with a lower tHRQOL score. The following characteristics were also associated (p Յ 0.05) with a lower tHRQOL score: sputum production (␤ ϭ Ϫ 0. 17), chronic cough (␤ ϭ Ϫ 0.14), and younger age (␤ ϭ 0.15). Current smoking was associated with a higher tHRQOL score (␤ ϭ 0.18). The percentage of variance in tHRQOL explained by the determinants in the reduced multivariate model was 45%. No significant contribution of prebronchodilator FEV 1 %pred to this model was found (data not presented in Tables).
Discussion
In both asthma and COPD, lower pulmonary function was associated with male gender and use of short-acting inhaled bronchodilators. In asthma, additionally, the most apparent associations were found with current smoking, region of living, longer duration of disease, and higher diurnal variation in PEF. In COPD, additional associations were found with use of long-acting bronchodilators; more days and nights disturbed by respiratory complaints; no history of wheezing; BHR; and, although not statistically significant, former smoking. Reduced HRQOL was, in both asthma and COPD, found to be most strongly associated with more days/nights disturbed by respiratory complaints and a higher dyspnea grade. Furthermore, associations were found with lower age, lower educational level, chronic cough, sputum production, and BHR (both diseases). In asthma, additional associations with a reduced HRQOL were found for region of living, comorbidity, use of inhaled bronchodilators and corticosteroids, and wheezing most days and nights. In COPD, furthermore, current smoking was associated with a better HRQOL. Both in asthma and COPD, almost half of the variation in HRQOL could be explained by the determinants in the multivariate models, with a relatively large contribution of respiratory symptoms, especially the number days/nights disturbed by respiratory complaints and dyspnea. For prebronchodilator FEV 1 %pred, however, only 16% (asthma) and 36% (COPD) of the variation could be explained by the determinants in the multivariate model. One striking finding is that in both asthma and COPD, male gender was (bivariately) associated with a lower pulmonary function and a better HRQOL. This is in accordance with results from a study done by Osborne et al, 19 who found that men with asthma reported a better quality of life than women. After we adjusted for other determinants in the multivariate model, the gender effect became nonsignificant for HRQOL. The fact that gender remains a significant determinant of pulmonary function even when the model is adjusted for other relevant determinants might indicate that men are more affected by their disease, resulting in lower pulmonary function (as a percentage of predicted) compared to women. Also Osborne et al 19 found that men with asthma have a lower prebronchodilator FEV 1 %pred. We chose to include region of living as a potential determinant in all models in order to adjust for the possible influence of different instruments used to assess pulmonary function. Because the spirometer used in the northwest differed from the one used in the other two regions, we expected to see differences regarding the level of pulmonary function when comparing this region with the other two regions. Although all bivariate coefficients were in the same direction, supportive of the idea that the spirometers used in the east and west might systematically produce higher levels of pulmonary function, multivariate results were less consistent. Only asthma patients living in the west, but not in the east, had a significantly higher pulmonary function. One possible explanation might be that in this region, patients receive a diagnosis earlier in their disease course. However, regional differences regarding pulmonary function must be interpreted carefully, because we cannot be sure that observed differences were not caused by different measurement conditions. The finding that living in the east and west was associated with a reduced HRQOL in asthma patients even after correction for other determinants might be caused by a different attitude toward disease between the different regions. This is an important finding to keep in mind when, for the purpose of epidemiologic studies, HRQOL is assessed in patients recruited from different areas. In asthma, current smoking was associated with a lower level of pulmonary function, which underlines the importance of smoking cessation in asthma patients. The finding that former smoking, not current smoking, was associated with a lower pulmonary function level in COPD patients might be explained by a "healthy smokers effect." Relatively healthy smokers are less motivated to quit smoking, while patients who do quit because of their disease (former smokers) are less healthy (have lower pulmonary function). In COPD, current smoking was associated with a better HRQOL, which may also be explained by the fact that patients who did not quit smoking (yet) are those with a less severe stage of disease. This finding is in contrast with findings of Prigatano et al, 36 in which COPD patients who continued smoking had a significantly lower quality of life than those who quit smoking.
Presence of allergy and wheezing was weakly associated with lower pulmonary function in asthma patients. Reverse associations were found in COPD patients, which might indicate that COPD patients who present with asthmatic features (such as wheezing and allergy) have better pulmonary function levels than other COPD patients; however, it should be kept in mind that this also might be the result of a not-entirely-correct separation in an asthma, COPD, and mixed-disease group.
In this study, we found diurnal PEF variation to be higher in COPD patients than in asthma patients. This is in contrast with the idea that because patients with asthma have a more variable pulmonary obstruction, they also have a higher diurnal PEF variation. 1 One possible explanation for this finding might be that some misclassification of asthma or COPD patients has occurred. In both asthma and COPD, a higher diurnal PEF variation was found to be associated with a lower level of pulmonary function. In a study done by van Schayck et al, 37 a higher diurnal PEF variation was predictive of a more rapid decline in pulmonary function in COPD patients, but no association was found in asthma patients.
In asthma patients, no associations were found between pulmonary function level and symptoms such as cough, sputum production, and days and nights disturbed by respiratory complaints. Weak associations were found with wheezing and dyspnea. This is in line with results from other studies that also found weak associations with wheezing 21, 22 and dyspnea, 21 but no associations with cough, sputum production, and nocturnal awakening. 22 Also, in COPD, no associations between pulmonary function level and symptoms were found, except for days and nights disturbed by pulmonary complaints and wheezing (wheezing in the opposite direction of expected). Although symptoms were poorly associated with pulmonary function, in this study they were the strongest determinants of HRQOL in both asthma and COPD. The explained variance of HRQOL, including all determinants in a multivariate model, was around 45% for both disease groups. Approximately the same percentage was found in another multivariate analysis from a cross-sectional study, 38 in which up to 50% of the variance in HRQOL could be explained by a range of measures, including, among others, cough, wheezing, and dyspnea.
In summary, pulmonary function appears to be poorly associated with respiratory symptoms and complaints in both asthma and COPD. HRQOL, however, which shows poor association with pulmonary function, does associate with respiratory symptoms and complaints. It seems that both pulmonary function and HRQOL highlight different aspects of disease severity and are both valuable in determining the actual disease state. This is in accordance with Ferrer et al, 39 who suggested that both pulmonary function and HRQOL should be used to evaluate patients with COPD. Also, Bailey et al 40 concluded that asthma severity appears to be multidimensional. This is important to consider not only when patients are seen in general practice, but when disease severity of patients with asthma or COPD is assessed in epidemiologic studies.
